A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of […]
The following publication describes a study developing the ROP-TB antigen for both in vitro IGRA-based TB diagnosis, as well as the in vivo skin test for TB diagnosis in both humans and cattle. The advantages of the ROP-TB diagnosis are firstly distinguishing Mtb infection from BCG vaccination, and secondly, being suitable for industrial manufacture. Read
From the eradication of smallpox through to the global response to the COVID-19 pandemic, vaccines have been a cornerstone in the fight against infectious diseases in humans and livestock since the 18th century. Although vaccines against COVID-19 are unlikely to eradicate the disease in the way that the smallpox vaccine did, they have proved very
Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines Read More »
HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study High-risk human papillomavirus (HPV) infection is the cause of almost all cervical cancers. HPV16 is one of the main risk subtypes. Although screening programs have greatly reduced the prevalence of cervical cancer in developed
HPV-16 E7-Specific Cellular Immune Response Read More »
Survivin (SVN) is a member of the inhibitor of apoptosis (IAP) protein family that promotes cellular proliferation and inhibits apoptosis. Overexpression of SVN is associated with autoimmune disease, hyperplasia, and tumors and can be used as a biomarker in these diseases. SVN is widely recognized as a tumor-associated antigen (TAA) and has become an important
Survivin as a biological biomarker for diagnosis and therapy Read More »
Therapeutic vaccines may well be the next wave of immunotherapy for cancer treatment. Peptide-based vaccines will play a pivotal role in the field. How is a peptide vaccine designed? What other factors such as adjuvants etc should be considered? Can Immunol oncological agents be synergetic with peptide vaccines? Read the full article: Beyond Just Peptide
Beyond Just Peptide Antigens: The complex world of peptide-based cancer vaccines Read More »
WHO Guideline – nonclinical_evaluation_vaccines_nov_2003
WHO guidelines on nonclincial evaluation of vaccines Read More »
Wang, Rosner and Roden – 2019 (view in PDF)
A Bayesian design for phase I cancer therapeutic vaccine trials Read More »